nonarrhythmogenic

the new drug is nonarrhythmogenic and safe for patients with heart disease.

researchers discovered a nonarrhythmogenic compound that lowers blood pressure.

this therapy is nonarrhythmogenic, making it suitable for long‑term use.

the study highlighted the nonarrhythmogenic effect of the natural supplement.

clinicians prefer nonarrhythmogenic agents when treating arrhythmia‑prone patients.

the nonarrhythmogenic property of the medication reduces risk of sudden cardiac death.

in clinical trials, the nonarrhythmogenic drug showed no pro‑arrhythmic side effects.

the new agent is marketed as a nonarrhythmogenic alternative to standard beta‑blockers.

the mechanism by which the compound is nonarrhythmogenic remains under investigation.

physicians evaluated the nonarrhythmogenic potential of the herbal extract.

the drug’s nonarrhythmogenic profile makes it a candidate for pediatric use.

our findings support the hypothesis that the molecule is nonarrhythmogenic.